PRECLINICAL DRUG DEVELOPMENT PROCESS OF RHEUMATOID ARTHRITIS MECHANISMS TO STUDY MORPHOLOGICAL CHANGES IN THE CELL AND VASCULAR STRUCTURE OF THE HEART IN EXPERIMENTAL ANIMALS

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

30 август 2023

Asosiy til:Ingliz

PRECLINICAL DRUG DEVELOPMENT PROCESS OF RHEUMATOID ARTHRITIS MECHANISMS TO STUDY MORPHOLOGICAL CHANGES IN THE CELL AND VASCULAR STRUCTURE OF THE HEART IN EXPERIMENTAL ANIMALS

Fan yo'nalishi:

64ef85bc63d8d.pdf

PDF

Журнал Кардиореспираторных исследований/ Journal of Cardiorespiratory Research/ Kardiorespirator tadqiqotlqr jurnali

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

Purpose of the study: to study the preclinical process of drug development of rheumatoid arthritis mechanisms to study morphological changes in the structure of cells and vessels of the heart in experimental animals Materials and Methods. Complete Freund's adjuvant for rheumatoid arthritis was applied to 100 white randomized rats aged between 18 and 24 months in the inpatient vivarium of the Bukhara State Medical Institute. Results and discussion: While investigating the preclinical drug development process of rheumatoid arthritis mechanisms to study morphological changes in the cell structure and vascular structure of the heart in experimental animals, it is important to note that animals do not naturally develop autoimmune diseases such as RA, which is an inherent limitation of these arthritis models. The results have shown that modern therapeutic approaches using modern biological agents are very successful and effective in most patients with RA, including those with severe disease progression.Conclusions: The presence of the influence of simulated rheumatoid arthritis on the heart was determined which testifies to the fact that this pathology has a sufficient level of risk for the organism.

MUALIFLAR

Teglar

# rheumatoid arthritis# cardiovascular risk

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0016/A0823-0188

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1. Agca R., Heslinga S.C., Rollefstad S. (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of infl ammatory joint 2. disorders: 2015/2016 update. Ann Rheum Dis., 76 (1), pp. 17–28. 3. Piepoli M.F, Hoes A.W, Agewall S, Albus C, Brotons C. (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and byinvited experts). Europ Heart J, 37(29), pp. 2315–2381. 4. Arida A., Protogerou A.D., Kitas G.D., Sfi kakis P.P. (2018) Systemic Infl ammatory Response and Atherosclerosis: The Paradigm of Chronic Infl ammatory Rheumatic Diseases. Int J Mol Sci., 19 (7),p. 1890. 5. Francula-Zaninovic S., Nola I.A. (2018) Management of Measurable Variable Cardiovascular Disease Risk Factors. Curr Cardiol Rev., 14 (3), pp. 153–163. 6. Cooney M.T, Vartiainen E, Laatikainen T, De Bacquer D, McGorrian C.(2012) Cardiovascular risk age: concepts and practicalities. Heart, 98, pp. 941–946. 7. England B.R., Thiele G.M., Anderson D.R., Mikuls T.R. (2018) Increased cardiovascular risk inrheumatoid arthritis: mechanisms and implications. BMJ, 23, p. 361. 8. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S.(2010) Screening for Cardiovascular Risk in Asymptomatic Patients J Am Coll Cardiol, 55, pp. 1169–77. 9. Karmali K.N., Persell S.D., Perel P. (2017) Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, issue 3. Art. No.: CD00688. 10. Kamilova U.K, Saidova M.M.(2019) Assessment of Cardiovascular Risk in Patients with Rheumatoid Arthritis Journal of "Cardiology in Belarus", 2019, volume 11, № 4, pp. 614–619 11. Willis A., Davies M., Yates T., Khunti K. (2012) Primary prevention of cardiovascular disease using validated risk scores: a systematic review. Journal of Royal Society of Medicine, 105 (8), pp. 348–56. 12. Crowson C.S., Gabriel Sh.E., Semb A.G. (2018) Rheumatoid arthritis-specifi c cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven 13. countries. Swiss Med Wkl, 22, p. 148. 14. Ташкенбаева Э. Н. и др. Механизмы кардиозащитных эффектов десфлурана и севофлурана во время реперфузии //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2. 15. Абдиева Г. А. и др. Особенности течения ишемической болезни сердца в сочетании с климактерической кардиопатией //Наука и образование: проблемы и стратегии развития. – 2017. – Т. 2. – №. 1. – С. 26-29.